Apollomics Inc., a biopharmaceutical company, has announced a secondary offering of 19,166,666 Class A ordinary shares. The shares are being offered by selling securityholders pursuant to subscription agreements dated May 6, 2024. The offering is part of a registration rights agreement to satisfy registration rights granted by the company. The selling securityholders may sell the shares through public or private transactions at market prices or negotiated prices. The shares are listed on the Nasdaq Capital Market under the symbol 'APLM'. The company will not receive any proceeds from the sale of shares by the selling securityholders. Apollomics, incorporated in the Cayman Islands with operations in the U.S. and China, is considered an emerging growth company and a foreign private issuer, exempt from certain U.S. reporting requirements. The company has not paid dividends and does not anticipate doing so in the foreseeable future. The date of the prospectus is May 29, 2024.

Apollomics Inc., a biopharmaceutical company, has announced a secondary offering of 19,166,666 Class A ordinary shares. The shares are being offered by selling securityholders pursuant to subscription agreements dated May 6, 2024. The offering is part of a registration rights agreement to satisfy registration rights granted by the company. The selling securityholders may sell the shares through public or private transactions at market prices or negotiated prices. The shares are listed on the Nasdaq Capital Market under the symbol 'APLM'. The company will not receive any proceeds from the sale of shares by the selling securityholders. Apollomics, incorporated in the Cayman Islands with operations in the U.S. and China, is considered an emerging growth company and a foreign private issuer, exempt from certain U.S. reporting requirements. The company has not paid dividends and does not anticipate doing so in the foreseeable future. The date of the prospectus is May 29, 2024.